BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nanosyn Inc. And Amphora Discovery Corporation Announce Collaborative Agreement


2/22/2006 12:34:48 PM

MENLO PARK, Calif., and DURHAM, N.C., Feb. 22 /PRNewswire/ -- Nanosyn Inc. and Amphora Discovery Corporation today announced that they have entered into a multi-year research collaboration whereby Nanosyn will provide chemistry-based services to Amphora Discovery for multiple drug targets. Under the terms of the agreement Amphora will access a wide range of chemistry expertise offered by Nanosyn as well as their proprietary technologies allowing for cost-effective design and synthesis of biologically relevant small molecules. Amphora will own all compounds and their methods of use identified under the agreement. Nanosyn will receive an upfront fee, research funding, and success milestone payments for novel series identified in the collaboration. Nanosyn has already received success milestones from Amphora for two novel chemical scaffolds. No additional financial terms were disclosed.

"We are keen to expand on the very successful partnership that we currently have in place with Nanosyn for rapid, cost-effective chemistry services," stated C. Nicholas Hodge, Ph.D., Chief Scientific Officer and Founder of Amphora Discovery. "By extending the collaboration, we are able to tap into Nanosyn's full range of capabilities in complex, innovative chemistry. This relationship strengthens Amphora's ability to move multiple safe, targeted drugs into clinical trials."

"We are delighted to see that our relationship with Amphora Discovery has developed into a fully integrated chemistry collaboration," said Nikolai Sepetov, President and CEO of Nanosyn. "I believe that Amphora's unique set of chemical biology tools and Nanosyn's chemistry capabilities are truly complementary, allowing for rapid advancement of drug discovery programs at Amphora."

About Amphora Discovery

Amphora Discovery Corporation is a privately held pharmaceutical research company skilled in the science and art of pathway-based drug discovery. Its lead generation platform delivers unmatched precision, selectivity and data quality, which has produced well characterized proprietary new clinical entities for use in oncology, inflammation, metabolic diseases and neurological disorders. Amphora has multiple compounds being prepared for clinical studies in the areas of oncology and inflammation. Amphora is based in the Research Triangle Park, North Carolina, with offices in Los Altos, California. For more information, visit the company's web site at www.amphoracorp.com

About Nanosyn Inc.

Nanosyn is a medicinal chemistry based organization providing made-to-order focused compound libraries, hit-to-lead optimization, medicinal chemistry services, and other innovative solutions to meet our partners drug discovery needs. Nanosyn's "Chemistry on Demand" capabilities enable customers to apply the power of new screening technologies without making frustrating trade-offs between budgets, schedules, and research opportunities. The company's proprietary technology and processes build the best organic synthesis strategies available into strategic configurations of instrumentation, software and reagents, and uses real-time analytical data to orchestrate organic synthesis events. Founded in 1998, Nanosyn is privately held and self-funding. The company is based in Menlo Park, California. For more information, visit the company's web site at www.nanosyn.com

Nanosyn Inc.

CONTACT: Olga Issakova for Nanosyn Inc., +1-650-269-3528



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES